StreetInsider.com News Articles

Form 8-K enGene Therapeutics Inc. For: Jul 17

Fri, 17 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260717/26784366.html

Form 8-K enGene Therapeutics Inc. For: Jul 17

Fri, 17 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260717/26784366.html

Form 8-K enGene Therapeutics Inc. For: Jul 15

Thu, 16 Jul 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260716/26776991.html

Form 8-K enGene Therapeutics Inc. For: Jul 15

Thu, 16 Jul 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260716/26776991.html

enGene names new board chairman ahead of planned BLA filing

Thu, 16 Jul 2026 08:01:17 -0400

enGene Therapeutics Inc. (Nasdaq: ENGN) announced changes to its board of directors, with Michael Heffernan assuming the role of chairman and Dr. Richard Glickman stepping down after more than 14 years in the position.

Heffernan has served on enGene's board since July 2025. He is the founder of Collegium Pharmaceutical and has previously held leadership roles at Onset Dermatologics, Clinical Studies Ltd., and Eli Lilly and Company. He currently serves as chairman at NMD Pharma, Avalo Therapeutics, and AAVantgarde Bio, and as a board member at Biohaven, Trevi Therapeutics, and K36 Therapeutics.

The board changes come as enGene plans a pre-Biologics License

enGene names new board chairman ahead of planned BLA filing

Thu, 16 Jul 2026 08:01:17 -0400

The board changes come as enGene plans a pre-Biologics License

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing,

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Thu, 16 Jul 2026 08:00:00 -0400

Michael Heffernan assumes the role of Chairman of the Board

Dr. Richard Glickman to step down

Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026

Initiation of BLA submission for detalimogene planned for 2H 2026

Potential FDA approval of detalimogene in 2027

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

Wed, 15 Jul 2026 09:00:00 -0400

The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.
Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

Wed, 15 Jul 2026 09:00:00 -0400

The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.
Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

Wed, 15 Jul 2026 09:00:00 -0400

The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.
Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.